# Pharmacokinetics and Safety/Tolerability Profile of CKD-379

> **NCT05452525** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 24 (actual)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** CKD-379 I
- **DRUG:** CKD-379 II
- **DRUG:** D759+D745+D150

## Key facts

- **NCT ID:** NCT05452525
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-26
- **Primary completion:** 2022-08-27
- **Final completion:** 2022-09-21
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05452525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05452525, "Pharmacokinetics and Safety/Tolerability Profile of CKD-379". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05452525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*